2型糖尿病对COVID-19患者疾病严重程度、治疗效果及死亡率的影响
本研究纳入武汉大学人民医院2020年1月11日至2月6日连续收治的663例COVID-19患者,其中合并T2DM者67例(10.1%)。合并T2DM者更易发展为重型(58.2% vs 46.3%)和危重型(20.9% vs 13.4%)且治疗效果差(76.1% vs 60.4%),但两组死亡率无明显差异(4.5% vs 3.7%)。多因素分析显示T2DM与COVID-19治疗效果差相关(OR 2.99;95%CI 1.07-8.66;P=0.04)。
要点
- 合并T2DM的COVID-19患者更易出现重型与危重型,且治疗效果更差。
- T2DM是COVID-19治疗效果差的独立危险因素(OR 2.99;95%CI 1.07-8.66)。
- 合并T2DM者中重型/危重型病情与淋巴细胞减少是治疗效果差的独立危险因素。
核心结论
- T2DM影响COVID-19患者的疾病严重程度和治疗效果,是治疗效果差的独立危险因素之一。
- 合并与未合并T2DM的COVID-19患者死亡率无明显差异(4.5% vs 3.7%;P=0.732)。
研究设计与样本
- 回顾性纳入武汉大学人民医院2020年1月11日至2月6日连续收治的663例COVID-19患者,其中合并T2DM者67例(10.1%)。
主要发现
- 合并T2DM者年龄更大(66岁 vs 57岁;P<0.001),男性比例更高(62.7% vs 37.3%;P=0.019)。
- 合并T2DM者心血管疾病(61.2% vs 20.6%;P<0.001)和泌尿系统疾病(9% vs 2.5%;P=0.014)患病率更高。
- 合并T2DM者更易出现重型(58.2% vs 46.3%;P=0.002)和危重型(20.9% vs 13.4%;P=0.002)及治疗效果差(76.1% vs 60.4%;P=0.017)。
- 多因素logistic回归显示T2DM与COVID-19治疗效果差相关(OR 2.99;95%CI 1.07-8.66;P=0.04)。
- 合并T2DM者中重型/危重型病情(OR 3.27;95%CI 1.02-9.00;P=0.029)与淋巴细胞减少(OR 1.59;95%CI 1.10-2.34;P=0.016)是治疗效果差的独立危险因素。
临床怎么用
- 对合并T2DM的COVID-19患者应关注病情严重程度与治疗反应,警惕治疗效果差的风险。
- 合并T2DM者出现重型/危重型病情或淋巴细胞减少时,提示治疗效果可能更差。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Coronavirus disease 2019 (COVID-19) has become a topic of concern worldwide; however, the impacts of type 2 diabetes mellitus (T2DM) on disease severity, therapeutic effect, and mortality of patients with COVID-19 are unclear. METHODS: All consecutive patients with COVID-19 admitted to the Renmin Hospital of Wuhan University from January 11 to February 6, 2020, were included in this study. RESULTS: A total of 663 patients with COVID-19 were included, while 67 patients with T2DM accounted for 10.1% of the total. Compared with patients with COVID-19 without T2DM, those with T2DM were older (aged 66 years vs 57 years; P < 0.001) and had a male predominance (62.7% vs 37.3%; P = 0.019) and higher prevalence of cardiovascular diseases (61.2% vs 20.6%; P < 0.001) and urinary diseases (9% vs 2.5%; P = 0.014). Patients with T2DM were prone to developing severe (58.2% vs 46.3%; P = 0.002) and critical COVID-19 (20.9% vs 13.4%; P = 0.002) and having poor therapeutic effect (76.1% vs 60.4%; P = 0.017). But there was no obvious difference in the mortality between patients with COVID-19 with and without T2DM (4.5% vs 3.7%; P = 0.732). Multivariate logistic regression analysis identified that T2DM was associated with poor therapeutic effect in patients with COVID-19 (odd ratio [OR] 2.99; 95% confidence interval [CI], 1.07-8.66; P = 0.04). Moreover, having a severe and critical COVID-19 condition (OR 3.27; 95% CI, 1.02-9.00; P = 0.029) and decreased lymphocytes (OR 1.59; 95% CI, 1.10-2.34; P = 0.016) were independent risk factors associated with poor therapeutic effect in patients with COVID-19 with T2DM. CONCLUSIONS: T2DM influenced the disease severity and therapeutic effect and was one of the independent risk factors for poor therapeutic effect in patients with COVID-19.
引用
- Wang X, Liu Z, Li J, et al. Impacts of Type 2 Diabetes on Disease Severity, Therapeutic Effect, and Mortality of Patients With COVID-19. J Clin Endocrinol Metab. 2020. PMID: 32979271. doi:10.1210/clinem/dgaa535
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。